Abstract
PRO-140 is a humanized anti-CCR5 monoclonal antibody currently in phase II clinical development for the treatment of HIV. It has exhibited potent in vitro antiviral activity against a broad range of HIV-1 isolates. This antiviral activity has been confirmed in a number of clinical studies involving HIV-infected patients, with no drug-related serious adverse events reported.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 789-792 |
| Number of pages | 4 |
| Journal | Drugs of the Future |
| Volume | 34 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2009 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)